You are here

Nilotinib- the challenges from the patients point of view

This is a request for all CML patients who are currently being treated with nilotinib. I am due to attend a meeting in mid July (along with 2 other European Patient Advocates) with Novartis Europe in order that we can give feedback about the experience- both negative and positive- of therapy with nilotinib.  

I hope that those of you who have taken or are still taking this TKI will help others in the future, by sharing both the negative and positive experiences as you understand them. 

Please contact me at cmlsupportgroup@gmail.com

best wishes,

Sandy